000298170 001__ 298170
000298170 005__ 20250202015000.0
000298170 0247_ $$2pmid$$apmid:39836056
000298170 0247_ $$2ISSN$$a2042-6305
000298170 0247_ $$2ISSN$$a2042-6313
000298170 0247_ $$2doi$$aDOI:10.57264/cer-2024-0127 
000298170 0247_ $$2doi$$aDOI:10.57264/cer-2024-0127
000298170 0247_ $$2altmetric$$aaltmetric:173545483
000298170 037__ $$aDKFZ-2025-00189
000298170 041__ $$aEnglish
000298170 082__ $$a610
000298170 1001_ $$aThomas, Michael$$b0
000298170 245__ $$aMOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy.
000298170 260__ $$aRoyston, UK$$bBecaris Publishing$$c2025
000298170 3367_ $$2DRIVER$$aarticle
000298170 3367_ $$2DataCite$$aOutput Types/Journal article
000298170 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738151668_9464
000298170 3367_ $$2BibTeX$$aARTICLE
000298170 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298170 3367_ $$00$$2EndNote$$aJournal Article
000298170 500__ $$a2025 Feb;14(2):e240127
000298170 520__ $$aAim: MET exon 14 (METex14) skipping occurs in 3-4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical real-world data from patients with METex14 skipping NSCLC receiving conventional therapies. Given the rarity of this population and limitations of existing real-world data sources, the MOMENT registry aims to prospectively collect uniform, comprehensive, high-quality data from patients with METex14 skipping advanced NSCLC treated in routine clinical practice, which can support clinical and regulatory decision making. Patients & methods: MOMENT is a multinational, non-interventional disease registry collecting data on patients with METex14 skipping advanced NSCLC receiving any systemic anticancer therapy. Newly diagnosed patients and those already receiving treatment are eligible. Patients with previous participation in a clinical trial can be included if they receive at least one subsequent therapy line in a routine clinical setting. Eligible systemic treatment includes all available anticancer therapies (approved, conditionally approved or provided through Early Access). Data collection includes biomarker testing results, demographics, baseline clinical characteristics, treatment details and effectiveness, safety information and imaging. Registry site inclusion is dependent on confirmation that local METex14 skipping detection methods are sufficient to confirm METex14 skipping status. MOMENT is currently active at more than 60 sites across Europe and North America and approximately 700 patients are expected to be enrolled within the next 4 years. The first patient was enrolled on 4 October 2022. After completion of data collection, MOMENT data can be shared with external parties to conduct non-interventional studies. Discussion/conclusion: The MOMENT registry collects comprehensive, high-quality real-world data from patients with METex14 skipping advanced NSCLC receiving systemic anticancer treatment in a routine clinical setting, to enable future studies informing regulatory decisions and optimal care for this rare population. Clinical Trial Registration: NCT05376891 (ClinicalTrials.gov); EUPAS47602 (EU PAS register no.).
000298170 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000298170 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000298170 650_7 $$2Other$$aMETex14 skipping
000298170 650_7 $$2Other$$aNSCLC
000298170 650_7 $$2Other$$acancer registry
000298170 650_7 $$2Other$$areal-world data
000298170 650_7 $$2Other$$atargeted therapy
000298170 7001_ $$0P:(DE-He78)a22d618e20924210eb7b3af630a45441$$aChristopoulos, Petros$$b1$$udkfz
000298170 7001_ $$aIams, Wade T$$b2
000298170 7001_ $$aMazières, Julien$$b3
000298170 7001_ $$aCortot, Alexis B$$b4
000298170 7001_ $$aPeled, Nir$$b5
000298170 7001_ $$aMinuti, Gabriele$$b6
000298170 7001_ $$aSmit, Egbert F$$b7
000298170 7001_ $$aAudhuy, Francois$$b8
000298170 7001_ $$aBerghoff, Karin$$b9
000298170 7001_ $$aEggleton, S Peter$$b10
000298170 7001_ $$aFries, Frank$$b11
000298170 7001_ $$aHildenbrand, Maike$$b12
000298170 7001_ $$aLiu, Peter$$b13
000298170 7001_ $$aMahmoudpour, Seyed Hamidreza$$b14
000298170 7001_ $$aMenzel, Christoph$$b15
000298170 7001_ $$aOksen, Dina$$b16
000298170 773__ $$0PERI:(DE-600)2669725-7$$aDOI:10.57264/cer-2024-0127$$n2$$pe240127$$tJournal of Comparative Effectiveness Research$$v14$$x2042-6305$$y2025
000298170 909CO $$ooai:inrepo02.dkfz.de:298170$$pVDB
000298170 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a22d618e20924210eb7b3af630a45441$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000298170 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000298170 9141_ $$y2025
000298170 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-21
000298170 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-21
000298170 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-15T15:55:11Z
000298170 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-15T15:55:11Z
000298170 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2023-05-15T15:55:11Z
000298170 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-21
000298170 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-21
000298170 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-21
000298170 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-21
000298170 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-21
000298170 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-21
000298170 9201_ $$0I:(DE-He78)B063-20160331$$kB063$$lB063 Krebsgenomforschung$$x0
000298170 980__ $$ajournal
000298170 980__ $$aVDB
000298170 980__ $$aI:(DE-He78)B063-20160331
000298170 980__ $$aUNRESTRICTED